JUBLPHARMA — Jubilant Pharmova Balance Sheet
0.000.00%
Last trade - 00:00
- IN₹89.44bn
- IN₹115.06bn
- IN₹62.82bn
- 82
- 17
- 98
- 79
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 13,483 | 13,883 | 6,611 | 9,803 | 10,108 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 16,563 | 16,479 | 10,313 | 11,469 | 12,125 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 45,848 | 50,383 | 29,525 | 35,092 | 37,624 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 38,878 | 42,875 | 25,752 | 27,911 | 33,651 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 114,685 | 125,217 | 89,181 | 99,909 | 111,566 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 20,897 | 26,190 | 10,488 | 15,916 | 17,724 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 66,596 | 69,178 | 41,766 | 46,723 | 57,574 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 48,089 | 56,039 | 47,415 | 53,186 | 53,993 |
Total Liabilities & Shareholders' Equity | 114,685 | 125,217 | 89,181 | 99,909 | 111,566 |
Total Common Shares Outstanding |